Skip to content
‹ Back to IndustriesHealthcare

Surfacide experiences 500% Increase in Demand of Their Coronavirus Killing UV Robots

(Waukesha, WI)—January 5, 2021 – Surfacide®, the leader in hospital-grade, triple-emitter UV-C robot technology, is excited to announce they’ve moved to a larger facility in Waukesha, WI to accommodate rapid business growth at more than 500% in the past year. As we move into our new normal, germ-fighting, COVID-19 killing “robots” is being deployed everywhere…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share
Surfacide experiences 500% Increase in Demand of Their Coronavirus Killing UV Robots

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

(Waukesha, WI)—January 5, 2021 – Surfacide®, the leader in hospital-grade, triple-emitter UV-C robot technology, is excited to announce they’ve moved to a larger facility in Waukesha, WI to accommodate rapid business growth at more than 500% in the past year. As we move into our new normal, germ-fighting, COVID-19 killing “robots” is being deployed everywhere from hospitals, nursing homes, restaurants, hotels, gyms to commercial office spaces, tourist attractions, and professional sports stadiums. Surfacide has been a trusted leader in UV decontamination for over ten years due to its world’s only patented Helios® Triple-Emitter System of three virus-zapping robots.

Surfacide is actively being used throughout the world in over 500 leading healthcare facilities, children’s hospitals, nursing homes, correctional facilities, dental offices, hotels, restaurants, commercial businesses and more around the world. Such facilities include the Seattle Space Needle, Beachbody Studios, Children’s Hospital of Los Angeles and locally at Children’s Hospital of Wisconsin, Froedtert Medical College—Milwaukee and Aspirus Wausau Hospital. The company’s UV-C technology is scientifically validated to inactivate coronavirus–the family of virus that make up SARS-CoV-2 and COVID-19.

Surfacide’s new location is at N918 Northmound Dr., STE. 300 Waukesha, WI 53186 and the company’s new facility is more than 75,000 sq-ft, three times the size of their previous location. The company was started in a one-room office in 2010 and has experienced incredible and consistent growth every year since its inception. The expansive new building space will offer much needed space for Surfacide’s expanding team and to meet the huge increase in demand for their UV system since the pandemic hit. The facility will continue to house the company’s manufacturing and distribution arm, as well as a global training center, a state-of-the-art UV robot simulation room, conference rooms and offices.

Gunner Lyslo, Founder & CEO of Surfacide shares his excitement for the new space: “During the pandemic, we are fortunate to have grown our team and provide a proven UV-C technology that has tremendously impacted healthcare facilities, nursing homes, dental offices, and more in fighting the COVID-19 virus,” says Lyslo. “This year the importance of infection prevention has been paramount, and we expect to see that course continue in years to come. For as long as our communities need safety and protection, Surfacide will continue to evolve and be there to assist those who need it most.”

 About Surfacide

 Surfacide LLC and Surfacide Manufacturing Inc. are located in Waukesha, WI and produce multiple emitter UV-C systems. Surfacide is the only patented triple emitter UV-C system, providing the most efficient and flexible solution in the fight against viruses and bacteria that cause hospital-acquired infections. Hundreds of hospitals worldwide are using Surfacide technology to provide an extra layer of protection for patients and healthcare workers. Surfacide’s evidence-based UV-C solution reaches more surfaces, reduces shadowed areas, and requires less labor for a quicker turnaround time and better efficacy. Learn more about Surfacide by visiting https://surfacide.com or calling (844)-390-3538.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

TheraPanacea's CEO says software, not hardware, will scale radiotherapy

TheraPanacea's CEO says software, not hardware, will scale radiotherapy

TheraPanacea CEO Nikos Paragios said at ASTRO 2026 in Boston that vendor-agnostic AI software like ART-Plan can raise radiotherapy throughput on existing machines. A February 2025 Lancet Oncology study puts the global linac shortfall at 30%, with 36 of 181 countries owning no linac, limiting how far software alone can go.

  • 01A February 2025 Lancet Oncology study found a global median Linac Shortage Index of 130, a 30% capacity shortfall, and 36 of 181 countries with no linac at all.
  • 02Bundled adaptive systems already exist: Varian’s Ethos won FDA clearance in February 2020 and RaySearch demoed automated replanning at ASTRO, but buyers still need to validate acceptability and sign-off workflows.

Oct 29, 2026

Berg Insight expects 160 million home medical monitors in care programs by 2030

Berg Insight expects 160 million home medical monitors in care programs by 2030

Prescribed connected home medical monitors are forecast to grow from 92.7 million in 2025 to 159.7 million by 2030. Fastest growth is in diabetes, remote ECG and medication compliance, spread across many suppliers. Berg and IoT Business News argue value depends on integrating data into workflows.

  • 01159.7 million prescribed home medical monitors expected by 2030, growing at 11.5 percent annually from 92.7 million in 2025.
  • 02Sleep therapy is the largest connected segment, followed by diabetes with 19.5 million connections at end of 2025, with fastest future growth in diabetes, remote ECG and medication compliance monitoring.
  • 03Clinical value increasingly depends on integrating data across devices into workflows: vendors combine hardware, software, analytics and interoperability with existing healthcare systems.

Oct 26, 2026

Zocdoc's first acquisition in nearly 20 years is an insurance checker

Zocdoc's first acquisition in nearly 20 years is an insurance checker

Zocdoc has bought Sohar Health, its first acquisition in nearly 20 years. Sohar's software finds and verifies a patient's insurance coverage from a name and birth date. Zocdoc wants that check to work across its Care Access Network, which lets insurers, consumer apps and AI tools embed Zocdoc's clinician search and scheduling on their own websites and apps.

  • 01After nearly 20 years without an acquisition, Zocdoc's first purchase is the insurance check that sits between a patient's search and a booked appointment.
  • 02For practices that pay Zocdoc per booking, the sharper question is how often coverage verified at booking matches what the front desk confirms at check-in.

Oct 24, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512